Spreadsheet Update
Further to my previous kinase inhibitor spreadsheet, the updated version is now available (LINK). Glivec is still going great guns and showing no signs of slowing, and Tarceva is well on track for blockbuster status (even though it is currently not used in first line/adjuvant settings in NSCLC - LINK). Seems like Tykerb is off to a decent enough (if unexceptional) start although it was never predicted to be a stunning seller ($380m-$700m) (see article from NRDD here).
For those of you in analyst mode, you can use Excel to predict the Q4 sales (select the row of numbers plus one additional empty cell - Edit - Fill - Series - Type[AutoFill]).
The predictions come out as follows - Glivec $811m, Sutent $183m, Sprycel $52m, Iressa $54m, Nexavar $109m, Tarceva $258, Tykerb $44m.
Thank you for creating such an awesome spreadsheet. I do have a question about your work: Are you using worldwide sales or just US?
Comment by Anand — November 10, 2007 @ 2:04 pm
Sales are worldwide and are taken from the quarterly financial reports.
Comment by totallymedicinal — November 10, 2007 @ 4:02 pm